Exelixis, Inc. (EXEL)

Market Cap	6.99B
Revenue (ttm)	1.83B
Net Income (ttm)	207.77M
Shares Out	294.80M
EPS (ttm)	0.65
PE Ratio	36.48
Forward PE	18.85
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,466,092
Open	23.20
Previous Close	23.29
Day's Range	23.19 - 23.78
52-Week Range	18.08 - 24.34
Beta	0.57
Analysts	Buy
Price Target	26.79 (+12.99%)
Earnings Date	Apr 30, 2024

About EXEL

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 7, 2000
• Employees: 1,310
• Stock Exchange: NASDAQ
• Ticker Symbol: EXEL

Financial Performance

In 2023, Exelixis's revenue was $1.83 billion, an increase of 13.60% compared to the previous year's $1.61 billion. Earnings were $207.77 million, an increase of 13.98%.

Analyst Forecast

According to 14 analysts, the average rating for EXEL stock is "Buy." The 12-month stock price forecast is $26.79, which is an increase of 12.99% from the latest price.

Price Target

$26.79

(12.99% upside)

Analyst Consensus: Buy